Stability of Essential Drugs in Tropical Climates: Zimbabwe - EDM Research Series No. 013
(1994; 86 pages) Ver el documento en el formato PDF
Índice de contenido
Ver el documentoAbbreviations
Ver el documento1. Summary
Abrir esta carpeta y ver su contenido2. Introduction
Abrir esta carpeta y ver su contenido3. Study design and methods
Ver el documento4. Results
Abrir esta carpeta y ver su contenido5. Discussion
Abrir esta carpeta y ver su contenido6. Conclusions and recommendations
Ver el documentoReferences
Cerrar esta carpetaAnnexes
Cerrar esta carpetaAnnex 1: Detailed results for each drug
Ver el documento1.1 Amoxycillin capsules
Ver el documento1.2 Ampicillin capsules
Ver el documento1.3 Acetylsalicylic acid tablets
Ver el documento1.4 Doxycycline capsules
Ver el documento1.5 Ferrous sulfate tablets
Ver el documento1.6 Phenoxymethylpenicillin tablets
Ver el documento1.7 Tetracycline capsules
Ver el documento1.8 Retinol tablets
Ver el documento1.9 Epinephrine injection
Ver el documento1.10 Ampicillin injection
Ver el documento1.11 Benzylpenicillin injection
Ver el documento1.12 Ergometrine injection
Ver el documento1.13 Procaine penicillin injection
Ver el documentoAnnex 2: Validation of laboratory results
 

1.13 Procaine penicillin injection

SHELF LIFE

Manufacturer A: 2 years

ASSAY METHOD

Spectrophotometric method, BP 1988 p, 840/Addendum 1989. Contents of 10 vials mixed and measured three times; mean taken.

ASSAY LIMITS

90 - 110% (BP)

SAMPLES OBTAINED

Manufacturer A

GMS samples

no.

%

Total

25

100

Harare

16

64

Bulawayo

9

36

Facility samples

no.

%

Total

72

100

Age > 50% SLife

2

3

Facility type = PCH

58

81

Climate = hot

53

74

Transport = slow

46

64

Longitudinal series

   

Total

42

100

SUMMARY ASSAY RESULTS

GMS samples

All Manuf.

     

Mean age (mths)

 

1.5

     

Mean assay

 

101.0%

     

95% CL

99.3 - 102.8%

     

Mo. and % fail

0

0%

     

No. and % low fail

2

3%

     

No. and % high fail

0

0%

     

Facility samples

Manufacturer A

     

Mean age (mths)

 

6.0

     

Mean assay

 

98.3%

     

95% CL

96.9 - 99.7%

     

No. and % fail

3

4%

     

No, and % low fail

2

11%

     

No. and % high fail

0

0%

     

Longitudinal series

at manufacturer

at GMS

at facility

Mean age (mths)

 

0

 

1.4

57

Mean assay

 

101.2%

 

101.2%

97.3%

95% CL

100.2 - 102.1%

99.9 - 102.6%

95.3 - 99.4%

No, and % fail

0

0%

0

0%

3

7%

 

Mean interval (mths)

4.3

 

Mean loss (-) or gain (+)

-3.6%

 

95% CL for loss/gain

-6.3 to -0.9%


Figure 1 - Results of GMS samples


Figure 2 - Results of facility samples

Findings:

a) No expired samples were found.

b) All 25 GMS samples were within assay limits (mean 101.0%). There was one borderline sample (92.0%).

c) Three of 72 facility samples (4%) failed; all failures were below the lower limit (72.2, 83.0, 85.0%). All three failures were from the same batch, the same geographical area and were transported by rail.

d) 42 GMS/facility sample pairs showed a mean loss of potency (-3.6%); the difference was statistically significant (t-test one tail, p=0.0001).

e) No initial quality problem was found.

f) A modest instability problem was seen. Since the samples were in the early part of shelf-life, this is potentially more serious.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013